AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1832701
Drug: 9 capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9 capsules of fish oil daily for 6 months
Trial: 1832701
Drug: 12 capsules
RxNorm normalized name: nylon 12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 capsules of fish oil daily for 6 months
Trial: 1832701
Drug: All doses
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All doses except the lowest
Trial: 1832701
Drug: Highest dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Highest dose (12 capsules)
Trial: 1832701
Drug: Two middle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two middle doses (6 and 9 capsules)
Trial: 6227208
Drug: 24 hour
RxNorm normalized name: Immune 24 Hour +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 hour urinary noradrenaline excretion (in upper blood pressure range)
Trial: 6227208
Drug: Plasma insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma insulin (in intermediate blood pressure range)
Trial: 29962429
Drug: PYC chewing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PYC chewing gum (2.5 mg per piece, 2 pieces, 6 times daily for 15 min)
Trial: 21853290
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg tolvaptan with 240 mL of reconstituted grapefruit juice
Trial: 21853290
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg tolvaptan with 240 mL of water
Trial: 11877767
Drug: High-dose myeloablative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose myeloablative radioimmunotherapy with (131)I-labeled chimeric anti-CD20 antibody C2B8 at doses of 261-495 mCi, with a protein dose of 2.5 mg/kg (or 10 mg/kg for one patient with splenomegaly).
Trial: 11877767
Drug: High-dose myeloablative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose myeloablative radioimmunotherapy with (131)I-labeled chimeric anti-CD20 antibody C2B8.
Trial: 10223779
Drug: All doses
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All doses of lanreotide
Trial: 2367653
Drug: Blood patch
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood patch technique (group A)
Trial: 2367653
Drug: No blood
RxNorm normalized name: VivaGuard Ino Blood Glucose Meter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No blood patch (group B)
Trial: 30797042
Drug: Buprenorphine Bridge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine Bridge Treatment (BBT)
Trial: 20589922
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg paliperidone ER OROS
Trial: 20589922
Drug: 9 mg
RxNorm normalized name: fiber 469 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9 mg paliperidone ER OROS
Trial: 17379842
Drug: Fluvastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin (20 mg/d)
Trial: 17379842
Drug: Colestimide (3000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colestimide (3000 mg/d)
Trial: 12193911
Drug: Intravenous oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous oxytocin (1 to 4 mU/min) and placebo intravaginal misoprostol
Trial: 12193911
Drug: Intravaginal misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravaginal misoprostol (50 microg, repeated at 4 hourly intervals if <3 uterine contractions per 10 minutes)
Trial: 8520442
Drug: Albendazole (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albendazole (15 mg/kg/day for 7 days)
Trial: 2361796
Drug: Topical aluminium
RxNorm normalized name: Aluminium
DrugBank: Aluminium phosphate (DB14517)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical aluminium chloride hexahydrate 20% W/W ethanol (ACH) applied daily for 4 weeks
Trial: 415471
Drug: Sulpiride 50
RxNorm normalized name: sulpiride 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulpiride 50 mg injection
Trial: 27696656
Drug: Triple intrathecal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple intrathecal therapy without cranial radiation (CrRT)
Trial: 25680375
Drug: Targeted therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted therapy (specific agents not detailed)
Trial: 23640544
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) delivered by a psychologist plus treatment as usual (education, reassurance, and symptom management strategies)
Trial: 23640544
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (education, reassurance, and symptom management strategies)
Trial: 21533329
Drug: Internet-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based cognitive behavioural treatment
Trial: 15090770
Drug: GW433908/ritonavir (908/r)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GW433908/ritonavir (908/r) 1400 mg/200 mg, once daily (q.d.)
Trial: 15090770
Drug: Nelfinavir 1250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nelfinavir 1250 mg, twice daily (b.i.d.)
Trial: 11274623
Drug: Eradication therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eradication therapy (120 mg of bismuth subcitrate, 500 mg of tetracycline, and 400 mg of metronidazole, all given four times daily for one week)
Trial: 11274623
Drug: Omeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (20 mg daily for six months)
Trial: 9636912
Drug: Heparin-coated circuits
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-coated circuits (n = 11)
Trial: 28503741
Drug: Autologous platelet-rich
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous platelet-rich plasma injection
Trial: 26301701
Drug: brexpiprazole 2
RxNorm normalized name: brexpiprazole 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: brexpiprazole 2 mg/d
Trial: 23178320
Drug: Low nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low nicotine (LN, 0.4 mg/g)
Trial: 23178320
Drug: High nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High nicotine (HN, 11.4-12.8 mg/g)
Trial: 23178320
Drug: Intermediate nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermediate nicotine (IN, 5.7-5.8 mg/g)
Trial: 18297436
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment schedule (three treatment sessions per week for the first 2 weeks)
Trial: 18297436
Drug: Original treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Original treatment schedule (weekly treatment)
Trial: 16296399
Drug: Microalgae oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microalgae oil (0.94 g DHA/d)
Trial: 15289837
Drug: CDDP (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDDP (80 mg/m(2)) as a continuous 2‐h intravenous infusion on day 1 and 5‐FU (700 mg/m(2)) as a continuous intravenous infusion on days 2‐5 (Group A)
Trial: 15289837
Drug: 5‐FU (700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐FU (700 mg/m(2)) as a continuous intravenous infusion on days 1‐4, followed by CDDP (80 mg/m(2)) as a continuous 2‐h intravenous infusion on day 5 (Group B)
Trial: 11762807
Drug: Oral vinorelbine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vinorelbine at 60 mg/m2/week for the first three administrations, then increased to 80 mg/m2/week
Trial: 11762807
Drug: Intravenous (i.v.)
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (i.v.) vinorelbine at 30 mg/m2/week
Trial: 8996153
Drug: Combined chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined chemotherapy (CT) plus radiotherapy (RT): cisplatin 75 mg/m2 on day 1 and fluorouracil (5FU) 1,000 mg/m2/d on days 1 to 4 every 4 weeks with RT and every 3 weeks post‐RT.
Trial: 8996153
Drug: Combined chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined chemotherapy (CT) plus radiotherapy (RT): additional patients treated with the same combined therapy.
Trial: 8435253
Drug: Oral diazepam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral diazepam 20 mg
Trial: 3315513
Drug: Insulin bolus
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin bolus at 2300 h (2.1 +/- 0.2 U)
Trial: 3315513
Drug: Insulin bolus
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin bolus at 0100 h (after reactivating the pump at 1.05 +/- 0.11 U/h)
Trial: 29596158
Drug: Spinal manipulative
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal manipulative therapy (SMT) combined with exercise therapy (ET)
Trial: 29596158
Drug: Exercise therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise therapy (ET) alone
Trial: 24461109
Drug: Pasireotide 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pasireotide 600 μg sc bid alone
Trial: 24461109
Drug: Pasireotide 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pasireotide 600 μg sc bid + Metformin 500 mg po bid
Trial: 24461109
Drug: Pasireotide 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pasireotide 600 μg sc bid + Nateglinide 60 mg po tid
Trial: 24461109
Drug: Pasireotide 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pasireotide 600 μg sc bid + Vildagliptin 50 mg po bid
Trial: 24461109
Drug: Pasireotide 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pasireotide 600 μg sc bid + Liraglutide 0.6 mg sc qd
Trial: 24461109
Drug: Pasireotide 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pasireotide 600 μg sc bid + Nateglinide
Trial: 24461109
Drug: Pasireotide 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pasireotide 600 μg sc bid + Metformin
Trial: 24461109
Drug: Pasireotide 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pasireotide 600 μg sc bid + Liraglutide
Trial: 24461109
Drug: Pasireotide 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pasireotide 600 μg sc bid + Vildagliptin
Trial: 22648092
Drug: Pomegranate juice
RxNorm normalized name: pomegranate juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomegranate juice (330 ml/day for four weeks)
Trial: 22648092
Drug: Control drink
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control drink (330 ml/day for four weeks)
Trial: 20099369
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of ebastine plus 120 mg of pseudoephedrine complex
Trial: 10406065
Drug: Adjunctive pharmacotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive pharmacotherapy with potent antiplatelet agents
Trial: 7574856
Drug: Testosterone undecanoate
RxNorm normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone undecanoate 20 mg once daily
Trial: 1058542
Drug: Four times
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four times repeated spray application
Trial: 1058542
Drug: Antiseptics added
RxNorm normalized name: Listerine Antiseptic
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiseptics added to the spray
Trial: 24997757
Drug: Ethinyl estradiol
RxNorm normalized name: Ethinyl Estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ethinyl estradiol and gestodene patch (delivering low doses equivalent to 0.02 mg EE and 0.06 mg GSD) applied once weekly for 3 weeks
Trial: 24997757
Drug: CYP3A4 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CYP3A4 inhibitors (erythromycin and ketoconazole) administered concurrently with the patch
Trial: 24997757
Drug: Midazolam (CYP3A4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (CYP3A4 substrate) administered alone and after 3 weeks of concurrent patch application
Trial: 23351464
Drug: Percutaneous coronary
RxNorm normalized name: Glebionis coronaria whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous coronary intervention and optimal medical therapy
Trial: 15089890
Drug: Licofelone 200
RxNorm normalized name: Licofelone
DrugBank: Licofelone (DB04725)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Licofelone 200 mg b.i.d. (n = 30)
Trial: 15089890
Drug: Licofelone 400
RxNorm normalized name: Licofelone
DrugBank: Licofelone (DB04725)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Licofelone 400 mg b.i.d. (n = 30)
Trial: 15089890
Drug: Naproxen 500
RxNorm normalized name: naproxen 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen 500 mg b.i.d. (n = 30)
Trial: 15089890
Drug: Licofelone 200
RxNorm normalized name: Licofelone
DrugBank: Licofelone (DB04725)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Licofelone 200 mg b.i.d.
Trial: 15089890
Drug: Licofelone 400
RxNorm normalized name: Licofelone
DrugBank: Licofelone (DB04725)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Licofelone 400 mg b.i.d.
Trial: 15089890
Drug: Licofelone 200
RxNorm normalized name: Licofelone
DrugBank: Licofelone (DB04725)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Licofelone 200 mg b.i.d. or Naproxen therapy
Trial: 15089890
Drug: Licofelone or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Licofelone or Naproxen therapy
Trial: 11455257
Drug: Azathioprine (AZA)
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azathioprine (AZA) 2 mg/kg per day
Trial: 17460145
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (MMF) 1 g twice daily
Trial: 9726387
Drug: LAC (lansoprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAC (lansoprazole 30 mg b.d., amoxycillin 1 g b.d., clarithromycin 250 mg b.d.)
Trial: 9726387
Drug: LAM (lansoprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAM (lansoprazole 30 mg b.d., amoxycillin 1 g b.d., metronidazole 400 mg b.d.)
Trial: 9726387
Drug: LCM (lansoprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCM (lansoprazole 30 mg b.d., amoxycillin 1 g b.d., metronidazole 400 mg b.d.)
Trial: 8070443
Drug: Fluconazole (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole (3 mg/kg/day)
Trial: 8070443
Drug: Ketoconazole (7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole (7 mg/kg/day)
Trial: 20510523
Drug: High exposure
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High exposure group (≥500 mg/week)
Trial: 20510523
Drug: Moderate exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate exposure group (250-499 mg/week)
Trial: 20510523
Drug: Zero-low exposure
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zero-low exposure group (0-249 mg/week)
Trial: 11372922
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin type A (Botox) injections via percutaneous posterior‐lateral approach
Trial: 11372922
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin type A (Botox) injections via transnasal fiberoptic approach
Trial: 9425975
Drug: L2 group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L2 group (injection at the second lumbar vertebra)
Trial: 9425975
Drug: L4 group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L4 group (injection at the fourth lumbar vertebra)
Trial: 8276982
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg ibuprofen daily for 14 days in 4 divided doses
Trial: 8276982
Drug: No drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No drug regime (control group)
Trial: 31879077
Drug: Protein supplementation
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein supplementation (20-g protein-rich supplement)
Trial: 31879077
Drug: Carbohydrate supplementation
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate supplementation (20-g calorie-matched carbohydrate-rich supplement)
Trial: 30700175
Drug: GnRHa 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GnRHa 0.1 mg subcutaneous injection on day 3 after embryo transfer (ET)
Trial: 28100402
Drug: Late surfactant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late surfactant and inhaled nitric oxide
Trial: 28100402
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide alone (control)
Trial: 9150838
Drug: Inhaled amiloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled amiloride
Trial: 29862617
Drug: Trelagliptin 100
RxNorm normalized name: Trelagliptin
DrugBank: Trelagliptin (DB15323)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Trelagliptin 100 mg with insulin (A/A group)
Trial: 29862617
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with insulin (P/A group)
Trial: 26887502
Drug: Beverage containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beverage containing 55 mg BTP
Trial: 23241332
Drug: Dance group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dance group (n = 15) - cognitive-motor exercise program with dance video gaming, 12 weeks, twice weekly.
Trial: 23241332
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (n = 16) - strength and balance exercises only, 12 weeks, twice weekly.
Trial: 18515185
Drug: Transdermal rotigotine
RxNorm normalized name: rotigotine Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal rotigotine 1 mg over 24 h (n=115)
Trial: 18515185
Drug: Transdermal rotigotine
RxNorm normalized name: rotigotine Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal rotigotine 2 mg over 24 h (n=112)
Trial: 18515185
Drug: Transdermal rotigotine
RxNorm normalized name: rotigotine Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal rotigotine 3 mg over 24 h (n=114)
Trial: 15696321
Drug: Caffeine (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (1.2 mg/kg) after 8 hours of abstinence
Trial: 15696321
Drug: Caffeine (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (1.2 mg/kg) after 4 hours of abstinence
Trial: 386118
Drug: Aspirin (325
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (325 mg three times a day) and dipyridamole (75 mg three times a day)
Trial: 386118
Drug: Warfarin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin therapy (closely regulated)
Trial: 386118
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no antiplatelet or anticoagulant therapy)
Trial: 11211903
Drug: Propranolol (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (30 mg, administered orally once daily at 19:00 h for 14 days)
Trial: 11211903
Drug: Placebo (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (administered orally once daily at 19:00 h for 14 days)
Trial: 7927544
Drug: REmbIZ3 (rifampicin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: REmbIZ3 (rifampicin, ethambutol, isoniazid, pyrazinamide together in a single dose thrice weekly)
Trial: 2671282
Drug: Postoperative radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative radiation therapy and adjuvant doxorubicin and cyclophosphamide chemotherapy
Trial: 2671282
Drug: Postoperative radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative radiation therapy and chemotherapy
Trial: 793778
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg suloctidil t.i.d.
Trial: 793778
Drug: 1.5 mg
RxNorm normalized name: boron 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg dihydroergotoxine methylate t.i.d.
Trial: 28475201
Drug: Sensor-based balance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sensor-based balance training (4 weeks, twice a week) with real-time visual/audio feedback from wearable sensors.
Trial: 19834348
Drug: Caffeine-containing supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine-containing supplement (SUPP) - 400 mg caffeine, 66.7 mg capsicum extract, 10 mg bioperine, 40 mg niacin
Trial: 16096896
Drug: IV ampicillin
RxNorm normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV ampicillin (100 mg/kg/day divided every 6 h)
Trial: 16096896
Drug: IV ampicillin
RxNorm normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV ampicillin plus IV gentamicin (5 mg/kg as a single daily dose)